Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants-Reference-Cited by-同舟云学术

Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

Published:2009-01 Issue:2 Volume:284 Page:1313-1323
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Bottomley Matthew J.,Cirillo Agostino,Orsatti Laura,Ruggeri Lionello,Fisher Timothy S.,Santoro Joseph C.,Cummings Richard T.,Cubbon Rose M.,Lo Surdo Paola,Calzetta Alessandra,Noto Alessia,Baysarowich Jennifer,Mattu Marco,Talamo Fabio,De Francesco Raffaele,Sparrow Carl P.,Sitlani Ayesha,Carfí Andrea

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference38 articles.

1. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

2. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

3. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

4. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy

5. Characterization of novel mutations in the catalytic domain of the PCSK9 gene

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations;Frontiers in Pharmacology;2024-07-30

2. Computational analysis of propeptide‐containing proteins and prediction of their post‐cleavage conformation changes;Proteins: Structure, Function, and Bioinformatics;2024-05-22

3. Gallic Acid Can Promote Low-Density Lipoprotein Uptake in HepG2 Cells via Increasing Low-Density Lipoprotein Receptor Accumulation;Molecules;2024-04-26

4. LDLR c.415G > A causes familial hypercholesterolemia by weakening LDLR binding to LDL;Lipids in Health and Disease;2024-03-21

5. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08